ECHO 4 PWS: Orthopedics
When: Tuesday, December 17, 2024 at 5:00 PM EST
Where: Virtual/Zoom Video
This series is for healthcare providers only
PWSA | USA's - ECHO 4 PWS Healthcare Provider Series
PWSA | USA launched our new Healthcare Provider Project ECHO Series, ECHO 4 PWS, in 2023. We are proud to offer this opportunity to healthcare professionals who work with patients affected by Prader-Willi syndrome (PWS) and to be the first PWS organization to implement Project ECHO® in the United States.
Our next healthcare ECHO topic will take place on Tuesday, December 17, 2024, at 5:00 p.m. EST and will focus on Orthopedics and PWS presented by Dr. Harold van Bosse, followed by a 20-minute case study on PWS.
PWSA | USA’s Healthcare Provider Project ECHO Series will touch on a wide range of healthcare topics in the PWS space and will be available for all health professionals across our network including (but not limited to): Geneticists, Pediatric Endocrinologists, Neonatologists, Nurses, Pediatricians, Endocrinologists, Psychiatrists, Psychologists, Social Workers, Occupational Therapists, Pulmonologists, Orthopedic Surgeons, Dieticians, Physiotherapists, Speech and Language Therapists, Medical Students and Professional Caregivers.
While this ECHO series is only for healthcare providers to attend, recordings of the webinars are available for our PWS families to view HERE.
Scroll below to find more ECHO 4 PWS webinar opportunities.
Speaker
Harold van Bosse, MD
ECHO 4 PWS is Sponsored By
LEarn More about PWS Research
The (Sometimes Messy) Details of Life in a Clinical Trial
contributed by Anne Fricke, mom to Freya (13, living with Prader-Willi Syndrome) Freya’s third and fourth appointments for the Harmony TEMPO PWS trial to study whether pitolisant is an effective treatment for excessive daytime sleepiness (ESD) in individuals with PWS, were simply routine and a lot like the second appointment. Lab work, caregiver questionnaires, counting […]
Letter to Community on FDA’s Extension of DCCR Review
Dear PWS Families, We understand that hearing about the FDA’s extension of the review period for DCCR (diazoxide choline controlled release) may bring a mix of emotions, from hope to concern. Please know that this is a normal and expected part of the FDA’s thorough process, especially for a rare disease medication that has been […]
FDA Extends Review Period for DCCR: What It Means for the PWS Community
On Tuesday, November 26, 2024, Soleno Therapeutics shared an important development regarding the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets—a potential treatment for individuals with Prader-Willi syndrome (PWS) aged four and older who experience hyperphagia. The U.S. Food and Drug Administration (FDA) has extended the review period for this NDA, pushing the […]